Targeting the EGFR and immune pathways in squamous cell carcinoma of the head and neck (SCCHN): Forging a new alliance

Nabil F. Saba, Zhuo Gerogia Chen, Missak Haigentz, Paolo Bossi, Alessandra Rinaldo, Juan P. Rodrigo, Antti A. Makitie, Robert P. Takes, Primoz Strojan, Jan B. Vermorken, Alfio Ferlito

Research output: Contribution to journalReview article

Abstract

Despite the recent approval of immune-modulatory agents, EGFR inhibition continues to be a cornerstone in the management of squamous cell carcinoma of the head and neck (SCCHN) namely in combination with radiotherapy in the treatment of locoregionally advanced disease as well as in platinum-sensitive recurrent or metastatic disease in the first-line setting. Importantly, recent evidence has emerged supporting also an immune-modulatory effect of EGFR inhibition, and interest has now focused on utilizing these effects in the current treatment approaches for SCCHN. In this report, we review the rationale and evidence supporting the forging of this new alliance in optimizing the treatment of SCCHN.

Original languageEnglish (US)
Pages (from-to)1909-1915
Number of pages7
JournalMolecular Cancer Therapeutics
Volume18
Issue number11
DOIs
StatePublished - Jan 1 2019

Fingerprint

Platinum
Radiotherapy
Therapeutics
Carcinoma, squamous cell of head and neck

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Saba, Nabil F. ; Chen, Zhuo Gerogia ; Haigentz, Missak ; Bossi, Paolo ; Rinaldo, Alessandra ; Rodrigo, Juan P. ; Makitie, Antti A. ; Takes, Robert P. ; Strojan, Primoz ; Vermorken, Jan B. ; Ferlito, Alfio. / Targeting the EGFR and immune pathways in squamous cell carcinoma of the head and neck (SCCHN) : Forging a new alliance. In: Molecular Cancer Therapeutics. 2019 ; Vol. 18, No. 11. pp. 1909-1915.
@article{a70b298300bc477baf0a0ae5b96bee24,
title = "Targeting the EGFR and immune pathways in squamous cell carcinoma of the head and neck (SCCHN): Forging a new alliance",
abstract = "Despite the recent approval of immune-modulatory agents, EGFR inhibition continues to be a cornerstone in the management of squamous cell carcinoma of the head and neck (SCCHN) namely in combination with radiotherapy in the treatment of locoregionally advanced disease as well as in platinum-sensitive recurrent or metastatic disease in the first-line setting. Importantly, recent evidence has emerged supporting also an immune-modulatory effect of EGFR inhibition, and interest has now focused on utilizing these effects in the current treatment approaches for SCCHN. In this report, we review the rationale and evidence supporting the forging of this new alliance in optimizing the treatment of SCCHN.",
author = "Saba, {Nabil F.} and Chen, {Zhuo Gerogia} and Missak Haigentz and Paolo Bossi and Alessandra Rinaldo and Rodrigo, {Juan P.} and Makitie, {Antti A.} and Takes, {Robert P.} and Primoz Strojan and Vermorken, {Jan B.} and Alfio Ferlito",
year = "2019",
month = "1",
day = "1",
doi = "10.1158/1535-7163.MCT-19-0214",
language = "English (US)",
volume = "18",
pages = "1909--1915",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

Saba, NF, Chen, ZG, Haigentz, M, Bossi, P, Rinaldo, A, Rodrigo, JP, Makitie, AA, Takes, RP, Strojan, P, Vermorken, JB & Ferlito, A 2019, 'Targeting the EGFR and immune pathways in squamous cell carcinoma of the head and neck (SCCHN): Forging a new alliance', Molecular Cancer Therapeutics, vol. 18, no. 11, pp. 1909-1915. https://doi.org/10.1158/1535-7163.MCT-19-0214

Targeting the EGFR and immune pathways in squamous cell carcinoma of the head and neck (SCCHN) : Forging a new alliance. / Saba, Nabil F.; Chen, Zhuo Gerogia; Haigentz, Missak; Bossi, Paolo; Rinaldo, Alessandra; Rodrigo, Juan P.; Makitie, Antti A.; Takes, Robert P.; Strojan, Primoz; Vermorken, Jan B.; Ferlito, Alfio.

In: Molecular Cancer Therapeutics, Vol. 18, No. 11, 01.01.2019, p. 1909-1915.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Targeting the EGFR and immune pathways in squamous cell carcinoma of the head and neck (SCCHN)

T2 - Forging a new alliance

AU - Saba, Nabil F.

AU - Chen, Zhuo Gerogia

AU - Haigentz, Missak

AU - Bossi, Paolo

AU - Rinaldo, Alessandra

AU - Rodrigo, Juan P.

AU - Makitie, Antti A.

AU - Takes, Robert P.

AU - Strojan, Primoz

AU - Vermorken, Jan B.

AU - Ferlito, Alfio

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Despite the recent approval of immune-modulatory agents, EGFR inhibition continues to be a cornerstone in the management of squamous cell carcinoma of the head and neck (SCCHN) namely in combination with radiotherapy in the treatment of locoregionally advanced disease as well as in platinum-sensitive recurrent or metastatic disease in the first-line setting. Importantly, recent evidence has emerged supporting also an immune-modulatory effect of EGFR inhibition, and interest has now focused on utilizing these effects in the current treatment approaches for SCCHN. In this report, we review the rationale and evidence supporting the forging of this new alliance in optimizing the treatment of SCCHN.

AB - Despite the recent approval of immune-modulatory agents, EGFR inhibition continues to be a cornerstone in the management of squamous cell carcinoma of the head and neck (SCCHN) namely in combination with radiotherapy in the treatment of locoregionally advanced disease as well as in platinum-sensitive recurrent or metastatic disease in the first-line setting. Importantly, recent evidence has emerged supporting also an immune-modulatory effect of EGFR inhibition, and interest has now focused on utilizing these effects in the current treatment approaches for SCCHN. In this report, we review the rationale and evidence supporting the forging of this new alliance in optimizing the treatment of SCCHN.

UR - http://www.scopus.com/inward/record.url?scp=85074436867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074436867&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-19-0214

DO - 10.1158/1535-7163.MCT-19-0214

M3 - Review article

C2 - 31676542

AN - SCOPUS:85074436867

VL - 18

SP - 1909

EP - 1915

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 11

ER -